Form 4 Filing for 4D Molecular Therapeutics, Inc. - Officer Transaction Report

This filing details transactions made by Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc. On June 30, 2026, Bizily acquired 814 shares of Common Stock at $4.14 per share and 5,752 shares of Common Stock at $6.49 per share. Additionally, Bizily disposed of 6,566 shares of Common Stock at $14.00 per share, a transaction made pursuant to a 10b5-1 trading plan. The filing also reports the disposal of 814 stock options with a conversion price of $4.14 and 5,752 stock options with a conversion price of $6.49. Post-transaction, Bizily holds 9,431 shares directly and 15,183 shares directly, with 62,971 and 3,543 options remaining respectively. The options vest over a four-year period.